Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following? -- Ignore unavailable to you. Want to Upgrade?

To: tom pope who wrote (1182)	12/15/2005 8:47:39 AM
From: Icebrg	Read Replies (2) \| Respond to of 2240

Medarex will be more difficult to swallow, though. Abgenix was more or less rudderless after spending most of their money on production facilities instead of products, having been forced to fire (one way or another) its CEO etc., etc. Medarex has been driven all along by a very ambitious Drakeman, their strategy has produced many more drug candidates etc. etc. And there is a poison pill provision in place. But the deal may well open the eyes on investors with regard to the potential in Medarex. Erik